Rossari Biotech’s board has approved the issuance of up to 30,12,046 equity shares of face value of Rs 2 each, on a preferential basis. The Board of Directors, in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable laws, determined a floor price of Rs 996 per Equity Share or such higher price, aggregating to Rs 300 crore. This preferential issue is subject to necessary approvals, including from the company’s shareholders.
The proposed issue will bring on board high-quality and marquee shareholders of scale and repute. The funds from this issue, if approved, will further strengthen the company’s balance sheet profile and will also augment the financial flexibility to address medium-to-long term growth prospects. The company proposes to utilize the net proceeds to evaluate & invest in inorganic growth opportunities, within its core chemistries, with a view to diversify its product portfolio, expand geographical reach and augment end-user industry applications. This will further enable the company to build a strong upcoming pipeline of new products, with impetus on sustainability and environment-friendliness.
Rossari Biotech is a specialty chemicals manufacturing firm with focus on home and personal care, performance chemicals, textile specialty chemicals and animal health and nutrition products. Apart from India, it has operations in 17 countries including Vietnam, Bangladesh and Mauritius.
| Company Name | CMP |
|---|---|
| BASF India | 3640.10 |
| Tata Chemicals | 809.45 |
| SRF | 2519.20 |
| Pidilite Inds. | 1375.55 |
| Deepak Nitrite | 1736.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: